

7 October 2021

AFRICANDO TRADE AND INVESTMENT CONFERENCE
HEALTH IS WEALTH ROUND TABLE DISCUSSION
LOCAL MANUFACTURING OF COVID 19 VACCINES:
CHALLENGES/OPPORTUNITIES AND DIASPORA CONTRIBUTIONS

m-RNA TECHNOLOGY HUB FOR AFRICA:
AN INCLUSIVE PARTNERSHIP MODEL TOWARDS SUSTAINABLE
VACCINE PRODUCTION IN AFRICA

PROF PETRO TERBLANCHE
MANAGING DIRECTOR
AFRIGEN BIOLOGICS AND VACCINES

## PRESENTATION OVERVIEW

COVID 19
CURRENT REALITY

AFRICA VACCINE MANUFACTURING LANDSCAPE

**TSUNAMI** 


mRNA Hub in South
Africa in the context of
COVAX objectives

QUA VADIS AFRICA?

### COVID-19 vaccine doses administered per 100 people, Sep 19, 2021



For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses per 100 people can be higher than 100.



# Africa faces 470 million COVID-19 vaccine shortfall in 2021



Image: https://www.un.org/africarenewal/magazine/june-2021/limited-supplies-slow-covid-19-vaccination-africa

- So far, around 2% of the nearly 6 billion doses administered globally have been administered in Africa.
- Africa has been able to fully vaccinate some 50 million people = 3.6% of the continent's population.

The 470 million doses, which are now expected to arrive by the end of December, are just enough to vaccinate just 17% of Africans on the continent.

#### **Vaccine manufacturing sites in Africa** and their vaccines **Institut Pasteur Morocco Institut Pasteur Algeria** BCG, DT, yellow fever, Rabies typhoid fever, Institut Pasteur de Tunis influenza, Lunisia BCG rabies Egy Vac (Vacsera) Morocco BCG-T, tuberculin, tetanus, Algeria typhoid, DTP, cholera Egypt **Ethiopian Public Health Institute** Plans to manufacture Senegal vaccines Nigeria Ethiopia **Institut Pasteur Dakar** Yellow fever **Innovative Biotech** Plans to manufacture vaccines 00 **Biovaccines** Plans to manufacture vaccines Biovac BCG, measles, pneumococcal conjugate, South 🔎 hepatitus B, DTP, polio, HIB and HepB Africa **Aspen Pharmacare** J&J Covid-19 ME Graphic: JOHN McCANN Data source: AFRICA CDC

AFRICA ACCOUNTS FOR ONLY 4% OF THE GLOBAL VACCINE MARKET BUT THE CONTINENT ONLY PRODUCES 1% OF ITS VACCINE REQUIREMENTS. THAT IN THE CONTEXT OF THE FACT THAT THE CONTINENT CONSUMES 25% OF GLOBAL VACCINES BY VOLUME.





#### **VIRTUAL CONFERENCE:**

# AFRICA'S VACCINE MANUFACTURING FOR HEALTH SECURITY

Monday 12th & Tuesday 13th April 2021

#### **Master of Ceremonies**

Opening Session: Mr Stepples Muchimba, Ag Director, African Union Commission

**Sessions 2-11:** Mr Chaacha Mwita, Consultant, Health Communication



# COVAX

CEPI








# Supply Chain & Manufacturing Task Force – Workstream 3

South Africa Hub Working Group

July 6, 2021

#### access to COVID-19 vaccines



## **EQUITABLE**

190 participating countries, incl. 92 low-and-middle income countries covered by free dose mechanism

**\$9.7B** pledges so far

**119M** doses delivered to **136** participants









Support COVAX mission to end acute phase of the pandemic by end 2021

Optimize the number of Vx doses manufactured in the short term

Prioritize doses for COVAX with a special emphasis on AMC92 to ensure greater equity

Mitigate unintended impact on other vaccines and health products

Initiate regional health security through establishment of sustainable regional long-term manufacturing of vaccines


# First vaccine technology transfer hub identified in South Africa – Key takeaways from WHO announcement on June 21st, 2021

#### WHO Media briefing on June 21st, 2021

Through COVAX, WHO announced it is supporting South African consortium to establish first COVID mRNA hub



Dr Tedros Adhanom Ghebreyesus OMS Director General



Cyril Ramaphosa South African president



Emmanuel Macron French president

#### **Key takeaways**



- Afrigen
- Biovac
- A network of universities



#### Follows WHO's call for EOI on April 16th, 2021

•28 offers received to either provide technology or to host a hub or both

#### Tech being identified with 2-pronged approach

- •"Late-stage" tech: fast & secured option (9-12 months) but with potential constraints
- "Early-stage" tech: lengthier & more uncertain, but offering broad scope / high program suitability

#### Next steps

- Confirm technology donor
- •Implement (governance, funding, etc.)
- Identify subsequent hubs, launch of EOI calls for other techs and recipients










## mRNA Vaccine Technology



#### **NON-LIVE**

- · No live pathogens
- · Sequence specificity
- Flexible product design
- · Well characterized

#### SAFETY

 RNA does not integrate into the host genome and is degraded once the protein is made

#### **IMMUNOGENICITY**

- Induces potent humoral and cellmediated immune responses
- Self-adjuvanting

#### **MANUFACTURING**

- · In vitro transcription
- · No cell culture
- Scalable to large capacity





# WS3 aims at creating global tech transfer hub / recipients network

Envisioning a global network of technology transfer hub(s) / recipients dedicated to LMIC uptake




Centralized hub(s) to facilitate multilateral technology transfers to regionally distributed LMIC recipients



LMIC recipients acquire technology and rapidly scale up production during pandemics



Recipient facilities pursue sustainable business models between pandemics







# Status: Partners collocating around SA hub to synergize & address short, medium & long-term Vx manufacturing challenges



French President, South Africa president & WHO DG announcing mRNA Hub creation in South Africa Public workshop held to present South Africa consortium, finalize Letter of Intent & initiate funding discussions Pfizerannounced partnership with Biovac for fill-finish of Covid mRNA vaccines

BioNTech announcing mRNA malaria vaccine development and co-location with the SA hub

July 26th






















6-9 Sept.

Field visit in South Africa to discuss funding, governance & facility/equipment preparation

Q3/Q4 and beyond

Other hubs/recipients (for mRNA & potentially other tech) to be selected and implemented

## **DISCONNECT?**



NRA-National Regulatory Authority, WHO-World Health Organisation, DCVM-Developing Countries Vaccine Manufacturers, BMGF-Bill and Melinda Gates Foundation, MNC-Multinationals Company

### **KEY DISCUSSION PIONTS**

- The lack of infrastructure is a key factor hampering the continent's economic development, trade and jobs creation.
- Prepare and Accelerate Public-Private Partnerships
- Regional integration is a key vehicle for helping Africa to raise competitiveness, diversify its economic base and create enough jobs for its young, fast-urbanizing population.
- The time has certainly come for Africa to start talking about what it is going to do for itself.
- Integration, integration, integration: it will make Africa stronger and benefit the world.


CONFIDENTIAL

# HARNESS OUR TALENT: KEY DETERMINANT OF A DESIRED FUTURE

- Africa's greatest resource is, and always has been: it will have 1.1 billion people of working age by 2040, a workforce greater than China's.
- To capitalize on the economic opportunity, the continent must invest in developing its human talent. The latest United Nations Human Development Index, ranks just four African countries as having "high" human development indicators.
- Skills development is crucial for building Africa over the next 50 years and, by that time, should no longer be one of the key issues constraining African development.

CONFIDENTIAL

## MANUFACTURING CAPACITY: ONE KEY DRIVER



# CREATING A CENTER OF EXCELLENCE: PARTNERSHIPS THE KEY

